Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
7.21
+0.02 (0.28%)
Aug 14, 2025, 12:06 PM - Market open
Amicus Therapeutics Employees
Amicus Therapeutics had 499 employees as of December 31, 2024. The number of employees decreased by 18 or -3.48% compared to the previous year.
Employees
499
Change (1Y)
-18
Growth (1Y)
-3.48%
Revenue / Employee
$1,144,609
Profits / Employee
-$76,345
Market Cap
2.22B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 499 | -18 | -3.48% |
| Dec 31, 2023 | 517 | 33 | 6.82% |
| Dec 31, 2022 | 484 | -12 | -2.42% |
| Dec 31, 2021 | 496 | 13 | 2.69% |
| Dec 31, 2020 | 483 | -101 | -17.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FOLD News
- 12 days ago - Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200 - Seeking Alpha
- 13 days ago - Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 16 days ago - In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data - GlobeNewsWire
- 24 days ago - Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewsWire
- 5 weeks ago - SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm - PRNewsWire
- 7 weeks ago - Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan - GlobeNewsWire
- 7 weeks ago - U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts - GlobeNewsWire